Belharra Therapeutics
PrivateLast Round
Series A
Jan 4, 2023
Total Funding Raised
$50M
Company Overview
Belharra Therapeutics is a biotechnology company that develops a photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously undruggable protein targets.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Belharra Therapeutics Comparables
Compare Belharra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BridGene Biosciences | 89% | |
| Nexo Therapeutics | 83% | |
| Frontier Medicines | 82% | |
Belharra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 4, 2023 |
Belharra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Versant Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 10, 2025
Sean Buchanan appointed as Chief Scientific Officer.
- Jan 4, 2023
$50M round led by Versant Ventures
Belharra Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Belharra Therapeutics's valuation, stock price, and market status.